Dubai, UAE – The Emirates Pharmaceutical Corporation announced the approval of the innovative drug “Baxfendi” (Baxfendy) for high blood pressure. Which contains the active ingredient “paxdrostat” (Baxdrostat), and is used in its concentrations of 1 mg and 2 mg. As an additional treatment option alongside antihypertensive medications in patients who are unable to adequately control their blood pressure levels.
The UAE is the first country in the world to grant approval for this treatment, developed by AstraZeneca (AstraZeneca). In a move that reflects its continued commitment to providing and accelerating the availability of pharmaceutical innovations, and enabling their adoption within flexible regulatory frameworks that support innovation and accelerate the adoption of specific treatments. To keep pace with sector developments and enhance the efficiency of pharmaceutical care, especially in the field of cardiovascular diseases.
Paxfendi helps lower blood pressure by inhibiting an enzyme responsible for producing the hormone aldosterone in the body. This provides a therapeutic approach that targets the root causes of the condition, especially in patients with uncontrolled high blood pressure despite receiving conventional treatments.
Enhancing drug security
Approval of Paxfendi was based on positive results from two phase III clinical trials, (BaxHTN) and (Bax24). Studies have shown statistically significant and clinically significant reductions in uncontrolled blood pressure levels when used in conjunction with standard treatments.
The adoption of this treatment comes as part of the Emirates Pharmaceutical Foundation’s efforts to enhance drug security and ensure the sustainable availability of innovative treatments. To enhance market stability and continuity of supplies.
It also contributes to raising the efficiency and readiness of the pharmaceutical system, in line with national trends towards building a flexible and sustainable pharmaceutical system that supports community health.
